EOLS (EVOLUS) thoughts on profitability story here, curious what people think
Been looking into Evolus for a while and figured I’d put my thinking out there. The injectable aesthetics space is changing a lot with the newer products being much more subtle than old school Botox, which used to give people that frozen look. That’s pulling in a younger crowd too, not just the usual demographic. Evolus themselves reckon the addressable market is around $19B. Right now it’s basically Galderma and AbbVie (who own Allergan/Botox) running the show, doing something like $2B and $4B a year respectively in this space, and the US market is notoriously hard to break into because of how expensive and slow FDA approval is.
What’s caught my attention is they’ve had two quarters in a row now of actual profitability - Q4 2025 came in with non-GAAP operating income of $7.1M which beat their own guidance, and then Q1 2026 posted positive adjusted EBITDA of $0.6M, which is notable because Q1 is usually their weakest quarter seasonally. Full year guidance for 2026 is $327-337M revenue with a low to mid single digit EBITDA margin, and by 2028 they’re guiding to $450-500M revenue at 13-15% margins. My thinking is once this turns into proper GAAP profitability rather than just adjusted EBITDA, the stock should re-rate, since it stops being a “trust me” growth story and becomes something a much wider pool of investors can actually own.
They’ve also just done a licensing deal with IBSA for Profhilo, which is the market leading skin quality injectable in Europe with something like 4.8 million treatments done since 2015. No upfront payments on that deal and management have said it doesn’t change their 2026 or 2028 guidance, so it’s a pretty capital efficient way to add a genuinely new category rather than just another neurotoxin competing with what they already have. If it lands well in the US alongside their existing two products, you could see a real three way market forming with AbbVie and Galderma.
CEO used to work at Allergan so he’s not new to this space, which I think matters.
On the balance sheet side they’ve got $49.8M cash, plus $100M they can still draw down from their Pharmakon loan facility on top of the $150M already drawn, and a $30M revolving credit line as well. So there’s real capital access beyond just what’s sitting on the balance sheet right now. On the flip side they’re carrying $156.4M in long term debt and technically have a stockholders deficit, so this isn’t some cash fortress like a lot of value plays, it’s a leveraged growth situation.
The bit I keep coming back to is that even with positive adjusted EBITDA, Q1 2026 still had a GAAP net loss of $10.7M and burned $10M in cash from operations. So the real test is whether that gap actually closes on the timeline they’re guiding to. If it does, I think this re-rates. If it drags on, probably doesn’t.
Interested to hear if anyone else here is following this one or has a different read on the category.